Boston Scientific's Farapulse Eyes Stronger US Market Position With Potential FDA Approval
Portfolio Pulse from Vandana Singh
Boston Scientific Corp (BSX) is set to present results from its ADVENT pivotal trial for the Farapulse Pulsed Field Ablation (PFA) system at the 2023 European Society of Cardiology Congress. The trial compares Farapulse to standard-of-care RF ablation and cryoballoon ablation. Analysts from Needham believe the trial could support FDA approval for Farapulse. The global electrophysiology market, valued at $7.6 billion in 2022, is projected to reach $9.4 billion by 2024. Boston Scientific's electrophysiology operations currently contribute about 5% of its revenue.
August 11, 2023 | 4:53 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Abbott holds a 25% share in the global electrophysiology market, which is projected to grow to $9.4 billion by 2024.
While Abbott is mentioned in the context of the electrophysiology market, the news does not directly impact the company. However, the projected growth of the market could potentially benefit Abbott.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50
NEUTRAL IMPACT
Johnson & Johnson holds a 48% share in the global electrophysiology market, which is projected to grow to $9.4 billion by 2024.
While Johnson & Johnson is mentioned in the context of the electrophysiology market, the news does not directly impact the company. However, the projected growth of the market could potentially benefit Johnson & Johnson.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50
NEUTRAL IMPACT
Medtronic Plc holds a 17% share in the global electrophysiology market, which is projected to grow to $9.4 billion by 2024.
While Medtronic is mentioned in the context of the electrophysiology market, the news does not directly impact the company. However, the projected growth of the market could potentially benefit Medtronic.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Boston Scientific's Farapulse PFA system could gain FDA approval, potentially strengthening its position in the electrophysiology market. The company's electrophysiology operations currently contribute about 5% of its revenue.
The potential FDA approval of Farapulse could bolster Boston Scientific's position in the electrophysiology market, which is projected to grow significantly by 2024. This could lead to an increase in the company's revenue and potentially its stock price.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100